Lupin Pharmaceuticals Inc. has released gatifloxacin ophthalmic solution 0.5%, an antibiotic for eye infections, in the United States.


Lupin Pharmaceuticals, gatifloxacin ophthalmic solution, Zymaxid Ophthalmic Solution, generic equivalent, Allergan, bacterial conjunctivitis, eye infections, antibiotic, Nilesh, Gupta








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Lupin launches generic version of Zymaxid

October 3rd, 2013

BALTIMORE – Lupin Pharmaceuticals Inc. has released gatifloxacin ophthalmic solution 0.5%, an antibiotic for eye infections, in the United States.

The company said Thursday that its product is the generic equivalent of Allergan Inc.'s Zymaxid Ophthalmic Solution, indicated for the treatment of bacterial conjunctivitis.

Lupin reported that it was the first applicant to file an abbreviated new drug application (ANDA) with the Food and Drug Administration for Zymaxid Ophthalmic Solution and will be entitled to 180 days of marketing exclusivity.

"Having received approval earlier, we are happy to now launch this product," stated Nilesh Gupta, managing director at Lupin Ltd., the India-based parent of Lupin Pharmaceuticals. "The product is the first of the ophthalmic products that Lupin is bringing to the market and bears testimony to our continued commitment to serving our customers and patients by bringing high-quality, affordable medicines."

More Supplier News Breaks >>
Advertisement